Concepedia

The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis

Sho Matoya, Takanori Suzuki, Kentaro Matsuura, Yuta Suzuki, Fumihiro Okumura, Yoshihito Nagura, Satoshi Sobue, Keita Kuroyanagi, Atsunori Kusakabe, Hiroki Koguchi,

Hepatology Research · 2023 · 21 citations · 34 references

DOIFull text

Open access

Abstract

The NLR-2c value predicts the initial therapeutic response and prognosis of patients with HCC treated with Atez/Bev therapy.

References

34

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

, , +9

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

Yoshinobu Kanda · Bone Marrow Transplantation · 2012 · 17.9K citations

Sorafenib in Advanced Hepatocellular Carcinoma

Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 12.8K citations · Full text

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · New England Journal of Medicine · 2020 · 6.8K citations · Full text

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.3K citations · Full text

, , +11